

Results Note

RM2.57 @ 24 November 2025

"Earnings a miss; We recommend that investors accept the offer price"

Share price performance



	1M	3M	12M
Absolute (%)	4.9	4.1	1.2
Rel KLCI (%)	4.5	2.7	-0.6

	BUY	HOLD	SELL
Consensus	-	2	1

Source: Bloomberg

Stock Data

Sector	Healthcare
Issued shares (m)	721.8
Mkt cap (RMm)/(US\$m)	1854.9/447.9
Avg daily vol - 6mth (m)	0.1
52-wk range (RM)	1.88-2.63
Est free float	21.2%
Stock Beta	0.96
Net cash/(debt) (RMm)	175.26
ROE (FY26E)	8.8%
Derivatives	No
Shariah Compliant	Yes
FTSE4Good	No
Constituent	
FBM EMAS (Top 200)	na
ESG Rank	

Key Shareholders

Apex Pharmacy Holding	39.6%
Washington H Soul	29.5%

Source: Affin Hwang, Bloomberg

Apex Healthcare (APEX MK)

HOLD (maintain)

Up/Downside: +2.7%

Price Target: RM2.64

Previous Target (Rating): RM2.64 (HOLD)

Associate losses continue to drag on earnings

- 3Q25 earnings were below expectations from larger associate losses coupled with lower margins within its core operations
- We lower our FY25E-27E earnings accordingly. The take-over offer price of RM2.64 implies a forward P/E of 26x, which is 2SD above its historical mean
- Maintain HOLD with an unchanged TP of RM2.64

Earnings below expectations

3Q25 core earnings of RM16m (-13% qoq, -19% yoy) brought 9M25 core earnings to RM52m (-19% yoy) which formed 66% of our previous full-year estimate (65% of consensus). Whilst revenue rose 7% on a yoy basis, the earnings were below expectations from larger-than-expected associate losses coupled with a larger portion of lower-margin distribution revenue.

Take-over offer price now even more attractive given the earnings miss

Following the results disappointment, we lower our FY25E-27E by 10-13% to reflect weaker margins and larger losses registered by its associate business. We do not foresee its associate business turning around in the near term, given the slower-than-expected recovery in orders coupled with much higher overheads arising from the relocation of operations to the new manufacturing campus at Batu Kawan Industrial Estate. The take-over offer price of RM2.64 implies a 26x forward P/E valuation, which is 2SD above its historical 5-year mean, making it an attractive price for investors to exit.

Maintain HOLD with an unchanged TP of RM2.64

Our target price is benchmarked against the recent take-over offer price of RM2.64. We recommend that investors accept the offer, if the acceptance condition is met, as it provides immediate liquidity given the potential for delisting. Furthermore, the earnings growth outlook of the company remains lacklustre, given the drag from its associate business coupled with the core business plateauing at a high base. We believe the stock is fairly valued as earnings momentum is expected to trend sideways in the near term.

Key upside/downside risks include: i) stronger-/ weaker-than-expected demand for pharmaceutical products; and ii) positive/adverse raw-material price fluctuations.

Earnings & Valuation Summary

FYE 31 Dec	2023	2024	2025E	2026E	2027E
Revenue (RMm)	936.2	961.8	1,011.6	1,033.6	1,061.1
EBITDA (RMm)	95.9	126.3	121.4	125.3	129.9
Pretax profit (RMm)	423.3	101.2	88.9	93.1	97.8
Net profit (RMm)	398.0	76.5	68.8	72.3	76.2
EPS (sen)	55.4	10.6	9.6	10.1	10.6
PER (x)	4.6	24.1	26.8	25.5	24.2
Core net profit (RMm)	94.6	83.2	68.8	72.3	76.2
Core EPS (sen)	13.2	11.6	9.6	10.1	10.6
Core EPS growth (%)	-2.2	-12.1	-17.3	5.1	5.4
Core PER (x)	19.5	22.2	26.8	25.5	24.2
Net DPS (sen)	22.5	9.0	7.5	5.5	6.0
Dividend Yield (%)	8.8	3.5	2.9	2.1	2.3
EV/EBITDA	15.3	13.3	13.4	12.7	12.0

Chg in EPS (%)	-12.7	-11.5	-10.4
Affin/Consensus (x)	0.9	0.8	0.8

Source: Company, Bloomberg, Affin Hwang forecasts

Andrew Lim

T (603) 2146 7586

E andrew.lim@affingroup.com



Fig 1: Results Comparison

FYE Dec (RMm)	3Q24	2Q25	3Q25	QoQ % chg	YoY % chg	9M24	9M25	YoY %chg	Comments
Revenue	237.4	240.8	253.0	5.1	6.6	724.3	732.6	1.2	Yoy improvements from increased sales and marketing efforts carried out over the preceding quarters
Op costs	-204.0	-209.2	-225.0	7.6	10.3	-632.7	-644.7	1.9	
EBITDA	33.4	31.5	28.0	-11.3	-16.3	91.6	88.0	-4.0	Weaker margins registered from a lower-margin product mix
<i>EBITDA margin (%)</i>	<i>14.1</i>	<i>13.1</i>	<i>11.1</i>	<i>-2ppt</i>	<i>-3ppt</i>	<i>12.6</i>	<i>12.0</i>	<i>-0.6ppt</i>	
Depn and amort	-5.1	-5.4	-5.2	-3.5	2.0	-14.5	-15.9	9.1	
EBIT	28.3	26.1	22.8	-12.9	-19.5	77.1	72.1	-6.4	
<i>EBIT margin (%)</i>	<i>11.9</i>	<i>10.9</i>	<i>9.0</i>	<i>-1.9ppt</i>	<i>-2.9ppt</i>	<i>10.6</i>	<i>9.8</i>	<i>-0.8ppt</i>	
Int expense	-0.6	-0.6	-0.5	-11.6	-21.5	-0.9	-1.6	75.4	
Int income	1.4	1.2	3.5	186.4	158.4	6.6	6.0	-9.1	Weakened outlook coupled with high overheads
Associates	-3.7	-2.6	-3.6	37.4	-1.1	-3.2	-7.8	145.4	
Exceptional items	-1.7	0.4	-0.5	-242.4	-69.0	-0.5	0.3	-154.5	
Pretax Profit	23.7	24.6	21.7	-11.7	-8.6	79.1	68.9	-12.9	
Tax	-5.5	-5.8	-6.1	5.4	10.9	-16.0	-17.0	6.0	
<i>Tax rate (%)</i>	<i>23.1</i>	<i>23.5</i>	<i>28.1</i>	<i>4.6ppt</i>	<i>4.9ppt</i>	<i>20.2</i>	<i>24.6</i>	<i>4.4ppt</i>	
Net profit	18.2	18.8	15.6	-17.0	-14.5	63.1	52.0	-17.6	Below our and consensus estimates
EPS (sen)	3.8	4.0	3.3	-17.0	-14.5	13.3	11.0	-17.6	
Core net profit	19.9	18.4	16.1	-12.5	-19.1	63.5	51.7	-18.6	

Source: Affin Hwang, Company

Important Disclosures and Disclaimer

Equity Rating Structure and Definitions

BUY	Total return is expected to exceed +10% over a 12-month period
HOLD	Total return is expected to be between -5% and +10% over a 12-month period
SELL	Total return is expected to be below -5% over a 12-month period
NOT RATED	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.

OVERWEIGHT	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
NEUTRAL	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
UNDERWEIGHT	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable and is not to be taken in substitution for the exercise of your judgment. You should obtain independent financial, legal, tax or such other professional advice, when making your independent appraisal, assessment, review and evaluation of the company/entity covered in this report, and the extent of the risk involved in doing so, before investing or participating in any of the securities or investment strategies or transactions discussed in this report. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (expressed or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, estimates, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel and the same are subject to change without notice. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest. Under no circumstances shall the Company, be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company its directors, its employees and their respective associates may have positions or financial interest in the securities mentioned therein. The Company, its directors, its employees and their respective associates may further act as market maker, may have assumed an underwriting commitment, deal with such securities, may also perform or seek to perform investment banking services, advisory and other services relating to the subject company/entity, and may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. The Company, its directors, its employees and their respective associates, may provide, or have provided in the past 12 months investment banking, corporate finance or other services and may receive, or may have received compensation for the services provided from the subject company/entity covered in this report. No part of the research analyst's compensation or benefit was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Employees of the Company may serve as a board member of the subject company/entity covered in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

Copyright © 2021 Sustainalytics. All rights reserved.

This report contains information developed by Sustainalytics. Such information and data are proprietary of Sustainalytics and/or its third-party suppliers (Third-Party Data) and are provided for informational purposes only. They do not constitute an endorsement of any product or project, nor an investment advice and are not warranted to be complete, timely, accurate or suitable for a particular purpose. Their use is subject to conditions available at <https://www.sustainalytics.com/legal-disclaimers>.

This report, or any portion thereof may not be reprinted, sold or redistributed without the written consent of the Company.

This report is printed and published by:
Affin Hwang Investment Bank Berhad (14389-U)
A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead,
69, Jalan Raja Chulan,
50200 Kuala Lumpur, Malaysia.
T : + 603 2142 3700
F : + 603 2146 7630
research@affinhwang.com
www.affinhwang.com

